Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Peking University People'S Hospital currently manages 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These 2 pending office actions are distributed across 2 distinct examiners and 2 distinct art units. This distribution shows that the hospital's active matters are being handled by different officials and administrative groups within the same technical field.
The busiest examiner for the hospital is GREENE, CAROLYN LEE, who is currently responsible for 1 busiest examiner pending office action. While the total number of pending office actions is higher than this individual's workload, the cases are split among the distinct examiners. This indicates that the hospital is experiencing multiple examination styles within the Biotechnology & Pharmaceuticals sector.
For patent practitioners, the presence of the 2 distinct art units requires a strategy that can adapt to different unit-specific standards. Although the busiest examiner only handles 1 busiest examiner pending office action, the overall activity is spread across multiple officials. This requires a distributed approach to ensure that the specific requirements of each examiner and art unit are addressed across the active cases.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| §112 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GREENE, CAROLYN LEE | 1 | 65.7% | +46.1% |
| GAO, ASHLEY HARTMAN | 1 | 56.5% | +38.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18717404 | USE OF RPN11 MARKER IN DETECTION OF MYELOMA AND DISEASE RISK THEREOF, PROGNOSIS ANALYSIS AND TREATMENT MEDICAMENT | GREENE, CAROLYN LEE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18717404 | USE OF RPN11 MARKER IN DETECTION OF MYELOMA AND DISEASE RISK THEREOF, PROGNOSIS ANALYSIS AND TREATMENT MEDICAMENT | GREENE, CAROLYN LEE | — |
| 18172516 | Antibody composition for immunotyping of myeloid tumor and use thereof | GAO, ASHLEY HARTMAN | — |
| Art Unit | Apps |
|---|---|
| 1681 | 1 |
| 1678 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18717404 | USE OF RPN11 MARKER IN DETECTION OF MYELOMA AND DISEASE RISK THEREOF, PROGNOSIS ANALYSIS AND TREATMENT MEDICAMENT | GREENE, CAROLYN LEE | 1681 | §101§102§103§112 | Non-Final OA | — | Pending | Jun 06, 2024 |
| 18172516 | Antibody composition for immunotyping of myeloid tumor and use thereof | GAO, ASHLEY HARTMAN | 1678 | §112 | Final Rejection | — | Pending | Feb 22, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPeking University People'S Hospital has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Carolyn Lee Greene has the most, with 1 of Peking University People'S Hospital's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
